Voyager Therapeutics (VYGR) Current Assets (2014 - 2026)
Voyager Therapeutics (VYGR) posted Current Assets of $147.0 million for Q1 2026, down 27.48% sequentially from $202.7 million in Q4 2025, and down 40.06% YoY from $245.2 million in Q1 2025.
Voyager Therapeutics (VYGR) Current Assets (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Current Assets for 13 years, with the latest figure at $147.0 million in Q1 2026.
- Quarterly Current Assets fell 40.06% year-over-year to $147.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147.0 million (down 40.06% YoY) and the FY2025 annual result came in at $202.7 million, down 26.78% from the prior year.
- Current Assets declined to $147.0 million in Q1 2026 per VYGR's latest filing, from $202.7 million in the prior quarter.
- Over five years, Current Assets peaked at $409.1 million in Q1 2024 and troughed at $124.5 million in Q4 2022.
- A 5-year average of $249.6 million and a median of $245.2 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets surged 156.78% in 2023, then tumbled 41.2% in 2025.
- Over 5 years, Current Assets stood at $124.5 million in 2022, then jumped by 156.78% to $319.7 million in 2023, then fell by 13.41% to $276.8 million in 2024, then declined by 26.78% to $202.7 million in 2025, then slipped by 27.48% to $147.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $147.0 million, $202.7 million, and $219.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 125.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.23 Mn |
| Mar 31, 2026 | 146.98 Mn |
| Dec 31, 2025 | 202.69 Mn |
| Sep 30, 2025 | 219.59 Mn |
| Jun 30, 2025 | 227.89 Mn |
| Mar 31, 2025 | 245.21 Mn |
| Dec 31, 2024 | 276.81 Mn |
| Sep 30, 2024 | 373.44 Mn |
| Jun 30, 2024 | 381.57 Mn |
| Mar 31, 2024 | 409.14 Mn |
| Dec 31, 2023 | 319.68 Mn |
| Sep 30, 2023 | 261.93 Mn |
| Jun 30, 2023 | 282.18 Mn |
| Mar 31, 2023 | 302.63 Mn |
| Dec 31, 2022 | 124.50 Mn |
| Sep 30, 2022 | 146.94 Mn |
| Jun 30, 2022 | 151.63 Mn |
| Mar 31, 2022 | 170.65 Mn |
| Dec 31, 2021 | 136.70 Mn |
| Sep 30, 2021 | 126.20 Mn |